razadyne has been researched along with Parkinson Disease in 2 studies
*Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becher, PG; Beuchat, J; Gademann, K; Jüttner, F | 1 |
| Mohamed, T; Rao, PP; Yeung, JC | 1 |
2 other study(ies) available for razadyne and Parkinson Disease
| Article | Year |
|---|---|
Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A.
Topics: Brain; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Galantamine; Humans; Inhibitory Concentration 50; Molecular Structure; Nostoc; Parkinson Disease | 2005 |
Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzhydryl Compounds; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Parkinson Disease; Plaque, Amyloid; Pyrimidines; Structure-Activity Relationship | 2011 |